天津打造天开高教科创园激发创新活力—— 科研成果在这里"破茧成蝶" 冬日的清晨寒风凛冽，天津市天开高教科创园又迎来忙碌的一天。在位于核心区5号楼20层的天津恩特 能源科技有限公司里，科研人员正在调试设备，屏幕上一组组数据快速跳动…… "科技创新策源地""科研成果孵化器""科创服务生态圈"……提起成立于2023年的天开高教科创园，人们 脑海中会闪过这些字眼。 两年多的时间里，天津市教委高标准服务天开园建设发展，充分调动全市教育优势资源，集聚技术、人 才等创新要素，加速推进天开园高质量发展。截至目前，全市高校已在天开园"一核两翼多点"累计注册 企业1000余家。如今，天开园已成为天津市高校科研成果转化的"梦工厂"。 打破制度藩篱，让科研工作者敢创业 签订了天开园第一份供销合同的恩特能源科技公司，经过两年多的发展已初具规模。"学校是我们强大 的后盾，不仅为公司提供了丰富客源，更是技术和人才的储备库。"恩特能源科技公司合伙人马小勇介 绍，公司依托天津大学王成山院士项目团队的技术成果，将先进的储能装备技术和产品在天开园落地转 化，主要服务于特种电源、储能及新能源发电等领域。 成立两年多来，天开园聚焦"政务、科创、金融、 ...

Core Insights - Liu Xin, a scientist from Yunnan, is dedicated to advancing the cell industry and transforming her respect for life into a driving force for innovation [2][3] Group 1: Background and Motivation - Liu Xin's childhood experiences with illness motivated her to pursue a career in medicine, leading her to study biochemistry and molecular biology at China Union Medical University [3] - After completing her PhD, she worked on vaccine development at the Chinese Academy of Medical Sciences and later studied in the United States, where she recognized the importance of translating research into practical applications [3][4] Group 2: Career Transition - In 2012, Liu Xin became an associate professor at Shanghai Jiao Tong University but felt a gap between basic research and practical application [4] - In 2014, she made the decision to leave academia for the industry to facilitate faster development and application of technology [4] - Inspired by the approval of a cell therapy for lymphoma in 2017, she decided to return to Yunnan to start a business focused on translating scientific research into practical solutions [4] Group 3: Entrepreneurship and Challenges - In 2018, Liu Xin co-founded Kunming Shiguangji Biological Technology Co., Ltd., facing challenges such as funding and talent acquisition [4][5] - The company started with a small team and gradually expanded to nearly 50 members by recruiting key personnel and training graduates [4][5] Group 4: Industry Development and Platform Building - Liu Xin identified common industry challenges such as long approval cycles and a lack of professional service platforms, leading her to establish a collaborative platform for the cell industry [5] - In 2019, her company partnered with a state-owned enterprise to create the Yunnan Cell Engineering Center, aiming to provide a one-stop service platform for the cell therapy sector [5] - The establishment of a testing center has significantly reduced costs and time for cell product testing, benefiting nearly 20 companies [5] Group 5: Talent and Future Vision - Liu Xin emphasizes the importance of talent in innovation, focusing on professional skills, practical spirit, and intrinsic motivation in her team [6] - The company aims to create an open, collaborative ecosystem among the 30+ enterprises in the park to lower innovation costs and foster synergy [6] - Liu Xin envisions developing the park into a leading international professional hub in Southwest China, leveraging Yunnan's unique biodiversity for innovative product development [6]

Core Viewpoint - The Chinese government is promoting the development of new application scenarios as a key driver for enhancing productivity, with Hefei actively facilitating the connection between innovative products and suitable application scenarios [1]. Group 1: Government Initiatives - The State Council issued implementation opinions to accelerate the cultivation and large-scale application of new scenarios, positioning them as crucial for developing new productive forces [1]. - Hefei has established a "scene working group" to identify and match technological capabilities with market needs, creating a bridge between supply and demand [7]. Group 2: Transportation Innovations - Hefei's Metro Line 4 transports over 250,000 passengers daily, supported by an intelligent system that utilizes quantum precision measurement technology and fiber optics for safety monitoring [3]. - The intelligent system can detect anomalies and deploy drones for safety inspections, showcasing the integration of innovative technology in public transport [5]. Group 3: Collaboration and Support - Hefei's government has invested initial funding to support technology companies in finding application scenarios, facilitating collaboration with state-owned enterprises for research and development [5]. - The city has published over 1,400 scenario opportunities and 1,500 capability listings, serving more than 4,100 technology enterprises and facilitating over 1,200 cooperative projects [9].

此次签约既是对双方前期合作成果的阶段性总结，更是高校与企业协同推动科研成果转化为国家战略生 产力的关键起点。当前核医学产业正迎来黄金发展期，原子高科凭借深厚行业积淀与鲜明产业特色，已 成为领域内核心力量。未来双方将以产学研协作为纽带，加速核心成果临床转化、搭建人才共育快车 道，参与全球核药新技术竞争，为我国核医学事业高质量发展筑牢根基。 中国同辐(01763)发布公告，2025年12月10日，原子高科股份有限公司(本公司旗下一间于全国中小企业 股份转让系统上市的附属公司)与北京师范大学在北京举办科技成果转化签约暨产学研合作交流会，共 同签署了氟[18F]贝他嗪项目《专利转让协议》与《产学研合作协议》。 氟[18F]贝他嗪是北京师范大学崔孟超教授团队与原子高科合作研发的成果，为具有完全自主知识产权 的一类新药，主要用于阿尔茨海默病的早期诊断。该药物在临床应用中表现出脑白质非特异性摄取显著 降低的特点，优于已获FDA批准的同类产品。 ...

智通财经APP讯，中国同辐(01763)发布公告，2025年12月10日，原子高科股份有限公司(本公司旗下一 间于全国中小企业股份转让系统上市的附属公司)与北京师范大学在北京举办科技成果转化签约暨产学 研合作交流会，共同签署了氟[F]贝他嗪项目《专利转让协议》与《产学研合作协议》。 此次签约既是对双方前期合作成果的阶段性总结，更是高校与企业协同推动科研成果转化为国家战略生 产力的关键起点。当前核医学产业正迎来黄金发展期，原子高科凭借深厚行业积淀与鲜明产业特色，已 成为领域内核心力量。未来双方将以产学研协作为纽带，加速核心成果临床转化、搭建人才共育快车 道，参与全球核药新技术竞争，为我国核医学事业高质量发展筑牢根基。 氟[F]贝他嗪是北京师范大学崔孟超教授团队与原子高科合作研发的成果，为具有完全自主知识产权的 一类新药，主要用于阿尔茨海默病的早期诊断。该药物在临床应用中表现出脑白质非特异性摄取显著降 低的特点，优于已获FDA批准的同类产品。 ...

格隆汇12月11日丨中国同辐(01763.HK)公告，以下公告的中文原稿由中国同辐股份有限公司旗下一间于 全国中小企业股份转让系统上市的附属公司，原子高科股份有限公司(股份代号：430005)于中国境内发 布。 氟[F]贝他嗪是北京师范大学崔孟超教授团队与原子高科合作研发的成果，为具有完全自主知识产权的 一类新药，主要用于阿尔茨海默病的早期诊断。该药物在临床应用中表现出脑白质非特异性摄取显著降 低的特点，优于已获FDA批准的同类产品。 此次签约既是对双方前期合作成果的阶段性总结，更是高校与企业协同推动科研成果转化为国家战略生 产力的关键起点。当前核医学产业正迎来黄金发展期，原子高科凭借深厚行业积淀与鲜明产业特色，已 成为领域内核心力量。未来双方将以产学研协作为纽带，加速核心成果临床转化、搭建人才共育快车 道，参与全球核药新技术竞争，为我国核医学事业高质量发展筑牢根基。 2025年12月10日，原子高科股份有限公司(以下简称"原子高科")与北京师范大学(以下简称"北师大")在 北京举办科技成果转化签约暨产学研合作交流会，共同签署了氟[18F]贝他嗪项目《专利转让协议》与 《产学研合作协议》。 ...

Group 1 - The core viewpoint of the article highlights significant fundraising activities in October 2025, with a total of 9 fundraising events amounting to over 180 billion RMB [1] - Brookfield has successfully raised a total of 20 billion USD for its clean energy fund, surpassing its initial target and becoming the largest private fund focused on clean energy transition globally [2][3] - The Hong Kong University of Science and Technology and Gobi Partners have established a strategic fund aimed at nurturing early-stage startups incubated by the university, focusing on commercialization of cutting-edge research [4][6] Group 2 - CICC Hebei Steel Development Equity Investment Fund has been established with a total scale of 32 billion RMB, focusing on private equity investments [5][7] - The Fujian Cultural and Tourism Digital Innovation Fund has officially launched with a total scale of 30 billion RMB, aimed at supporting innovation in the cultural and tourism sectors [5][8] - Prologis has completed fundraising for its first new materials and new energy-themed fund, with a total scale of 5 billion RMB [5][9][10] Group 3 - Kangqiao Capital's R-Bridge Healthcare Fund II has raised 500 million USD, focusing on investments in the healthcare sector [5][11] - Shanghai Xinjucyuan Fund has signed agreements with several high-tech enterprises, with a total scale of 4.5 billion RMB, targeting advanced manufacturing and other cutting-edge fields [5][12][13] - The China-Portuguese Economic and Trade Development Fund has been established with a total scale of 1 billion RMB, focusing on enhancing economic cooperation between China and Portuguese-speaking countries [5][14][15] Group 4 - Jiangsu Yangzhou Aerospace Industry Special Mother Fund's third sub-fund has been successfully registered with a total scale of 5 billion RMB, leveraging public selection for management [5][16] - The fourth Davos Global Mother Fund Summit is scheduled for January 2026, aiming to facilitate dialogue among global fund industry leaders [5][18][20] - The 2025 Global Best Investment Institutions ranking has commenced, highlighting the importance of recognizing top investment entities [5][23]

Core Insights - Recent trends show a decline in investor interest in professor-led entrepreneurial projects, despite a significant increase in the number of startups founded by researchers in Shanghai, which reached 153 companies with total financing exceeding 6.8 billion yuan in 2024 [1][2] - The contradiction between cooling investment enthusiasm and the ongoing success of research commercialization raises questions about the future of professor-led startups and the criteria for attracting investor support [1][2] Investment Trends - Investors are increasingly cautious about funding professor-led startups due to past failures attributed to personal factors, such as professors returning to academia or lacking full commitment to their ventures [1][2] - The shift in investor sentiment follows a previous trend where investors actively sought out professors to encourage entrepreneurship, leading to many projects being established under pressure [2] Successful Case Studies - Despite failures, several medical startups founded by researchers have successfully secured funding, including companies like Atake, Baiquan Bio, and Xueji Bio, which completed financing rounds in 2025 [2][3] - Notable examples include Xueji Bio, founded by Dr. Zhu Fangfang, who leveraged her venture capital experience to guide the company through multiple funding rounds, achieving significant milestones in clinical trials [4][5] Founding Team Characteristics - Successful startups often feature founders with prior entrepreneurial or commercialization experience, which enhances their appeal to investors [4][6] - Teams composed of top scientists and seasoned industry professionals are more likely to attract investment, as seen in companies like Baiquan Bio and Zhengxu Bio [6][7] Market Opportunities - The targeted protein degradation (TPD) sector has seen a surge in investment, with companies like Atake and Dage Bio successfully raising funds and advancing their pipelines [13][14] - The brain-computer interface sector is also gaining traction, with multiple companies completing financing rounds amid growing interest from investors [14] Evolving Investment Strategies - Investment institutions are adapting by focusing on the strengths of founding teams rather than solely on the academic credentials of professors, leading to a more balanced approach in evaluating potential investments [16][17] - Collaborative efforts among incubators, technology transfer offices, and industry leaders are creating supportive environments for researchers aiming to commercialize their innovations [15][16]

Core Insights - Gobi Partners is focusing on early-stage investments in sectors like biotechnology, AI, and robotics through its newly established Gobi-RIF fund, collaborating with Hong Kong University of Science and Technology and Hong Kong Investment Company [1][3] - The firm emphasizes its role as a lead investor, particularly in high-tech projects with unclear business models, leveraging its extensive experience and academic networks to assess the commercial viability of startups [6][10] Investment Strategy - Gobi Partners evaluates early-stage projects based on three dimensions: time, location, and team [7] - The time dimension focuses on whether the technology has reached a commercialization threshold and if market conditions are favorable [8] - The location dimension assesses the suitability of the startup's development in specific regions, particularly in Hong Kong and Greater Bay Area [8] - The team dimension prioritizes the founder's learning ability and the overall team's research capabilities [8] Collaboration and Support - The partnership with Hong Kong University and Hong Kong Investment Company aims to enhance the commercialization of university-incubated projects, providing early access to potential investments [4][5] - Gobi Partners plays a proactive role in connecting startups with resources, facilitating communication among founders, and assisting in government funding applications [9] Market Environment - The Hong Kong IPO market has seen a resurgence, with total fundraising exceeding HKD 210 billion in 2025, marking a four-year high, which provides a favorable exit environment for venture capital [3][10] - The introduction of listing rules 18A and 18C has created clearer pathways for biotech and long-cycle enterprises to go public, enhancing the investment timeline for venture capitalists [10][11]

Core Viewpoint - The "2025 Australia-China PhD Forum" held at the University of Melbourne focused on career development opportunities for young scholars, emphasizing the importance of interdisciplinary collaboration and the transformation of research outcomes into practical applications [1][3]. Group 1: Forum Overview - The forum attracted over 120 experts, scholars, and PhD students, featuring six guest speakers from academia, research institutions, and industry who shared their practical experiences [3][5]. - The event was organized by the Australia-China PhD Salon, which has been connecting academic forces and supporting young researchers since its establishment in 2006 [5]. Group 2: Key Discussions - Discussions included interpretations of Chinese technology policies, interdisciplinary collaboration, job-seeking experiences in the humanities and social sciences, and pathways for research entrepreneurship [5]. - Professor Wang Yaolin from the University of Melbourne highlighted the need for PhD students to enhance their communication skills and practical abilities while building networks for diverse career development [3]. Group 3: Strategic Insights - Peng Zhen, the representative of the China International Talent Exchange Association in Australia, noted the rapid evolution of the global technology landscape and encouraged young scholars in Australia to seize opportunities for contributing to national technological innovation [3].